NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $0.60 0.00 (0.00%) As of 11/11/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Ayala Pharmaceuticals Stock (NASDAQ:ADXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.60▼$0.6050-Day Range$0.60▼$0.6052-Week Range$0.00▼$0.80VolumeN/AAverage Volume15,632 shsMarket Capitalization$35.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ayala Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers. The company’s programs have centered on small-molecule treatments designed to address cancers driven by specific genetic alterations and signaling pathways. Ayala’s principal development programs included AL102, an investigational gamma-secretase inhibitor studied primarily for the treatment of desmoid tumors, and AL101, a related investigational therapy evaluated in patients with recurrent or metastatic adenoid cystic carcinoma. The company obtained rights to these programs and advanced them through clinical development, but they remained investigational and were not approved for commercial use. The company was formed through the combination of Advaxis, Inc. and Ayala Pharmaceuticals in 2020, after which the combined business adopted the Ayala Pharmaceuticals name and the Nasdaq ticker symbol ADXS. Ayala’s activities were focused on oncology research and development rather than the sale of marketed pharmaceutical products. Publicly available information about its later operations, leadership, and geographic commercial presence is limited.AI Generated. May Contain Errors. Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADXS Stock News HeadlinesAyala Pharmaceuticals, Inc. (ADXS) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comRockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapyFebruary 5, 2025 | bizjournals.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 13 at 1:00 AM | Porter & Company (Ad)OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineJanuary 29, 2025 | businesswire.comAyala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 10, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 7, 2024 | msn.comSee More Headlines ADXS Stock Analysis - Frequently Asked Questions How have ADXS shares performed this year? Ayala Pharmaceuticals' stock was trading at $0.0401 at the beginning of 2026. Since then, ADXS shares have increased by 1,405.1% and is now trading at $0.6036. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The firm had revenue of $250 thousand for the quarter. How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Ocugen (OCGN), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Guardion Health Sciences (GHSI) and Athersys (ATHX). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ADXS CIK1100397 Webadvaxis.com Phone609-452-9813Fax609-452-9818Employees20Year Founded2017Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.24 million Price / Sales11.05 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.29Miscellaneous Outstanding Shares59,305,000Free Float42,364,000Market Cap$35.79 million OptionableNot Optionable Beta1.75 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ADXS) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
